# Joan Huaqiong Shen

> Joan Huaqiong Shen is the founder and CEO of NeuShen Therapeutics, established in early 2022. Previously CEO of I-Mab, she held leadership roles at Eli Lilly, Wyeth, Pfizer, Jiangsu Hengrui and Janssen. Her career spans the United States and China; her personal account also describes a lifelong interest in music and the arts.

- **Role:** Founder & CEO at NeuShen Therapeutics
- **Organizations:** NeuShen Therapeutics, I-Mab Biopharma, Janssen / Johnson & Johnson, Jiangsu Hengrui Medicine, Pfizer, Wyeth, Eli Lilly and Company, Indiana University School of Medicine, Peking University, American Healthcare Executive Association
- **From:** Chengdu, China
- **Education:** MD, Southeast University Medical College, Master’s degree in anatomy, West China University of Medical Sciences, PhD in anatomy/neuroscience, Indiana University School of Medicine
- **Known for:** CEO during I-Mab’s January 2020 Nasdaq debut and September 2020 AbbVie partnership., Founded NeuShen Therapeutics in early 2022., Named to Endpoints News’ 20 Women in Biopharma R&D in 2021.

## Career timeline

- **2003-2005** — Clinical research physician at Eli Lilly and Company.
- **2005-2009** — Medical director at Wyeth Research.
- **2009-2011** — Senior medical director at Pfizer in the United States.
- **2011-2013** — Head of the China clinical department and senior director at Pfizer China.
- **2013-2015** — Chief medical officer and vice president at Jiangsu Hengrui Medicine.
- **2015-2017** — Vice president and development head at Janssen.
- **2017** — Joined I-Mab as head of discovery and clinical development in September.
- **2019** — Became an I-Mab director in July and CEO in October.
- **2020** — I-Mab began Nasdaq trading on January 17; the AbbVie partnership was announced in September.
- **2021** — Left the I-Mab CEO role on December 31.
- **2022** — Founded NeuShen Therapeutics in early 2022; received the BayHelix Woman Leader of the Year award.
- **2026** — NeuShen announced Series A+ financing in January and Series B financing exceeding $80 million in September.

## Achievements

- CEO during I-Mab’s January 2020 Nasdaq debut and September 2020 AbbVie partnership.
- Founded NeuShen Therapeutics in early 2022.
- Named to Endpoints News’ 20 Women in Biopharma R&D in 2021.
- Included in Forbes China’s Top 50 Women in Tech in 2021.
- BayHelix Woman Leader of the Year, 2022.

## Latest updates

- **2026-09** — NeuShen announced an oversubscribed Series B round exceeding $80 million on September 3.
- **2026-07** — NeuShen’s official news index announced new headquarters in Shanghai’s Zhangjiang Twin Towers on July 8.
- **2026-01** — NeuShen announced Series A+ financing led by Lilly Asia Ventures on January 28; the English website entry is dated February 2.

## Links

- Website: https://www.neushen.com/
- LinkedIn: https://www.linkedin.com/in/joan-huaqiong-shen-4714247

---

Profile page: https://yespress.io/joan-huaqiong-shen
Published by YesPress — https://yespress.io
Last updated: 2026-10-11